Advertising

The Seattle Times Company

NWjobs | NWautos | NWhomes | NWsource | Free Classifieds | seattletimes.com

Business / Technology


Our network sites seattletimes.com | Advanced

Originally published Wednesday, December 2, 2009 at 3:54 AM

Comments (0)     E-mail E-mail article      Print Print      Share Share

Hemispherx gets FDA denial on Ampligen treatment

Hemispherx Biopharma Inc. said Tuesday the Food and Drug Administration declined approval for the biotechnology company's experimental intravenous drug Ampligen as a treatment for chronic fatigue syndrome.

The Associated Press

PHILADELPHIA —

Hemispherx Biopharma Inc. said Tuesday the Food and Drug Administration declined approval for the biotechnology company's experimental intravenous drug Ampligen as a treatment for chronic fatigue syndrome.

The company said the FDA cited two key studies as not proving the drug is effective and recommends an additional study. Also, the FDA noted manufacturing issues that need to be resolved. Hemispherx is seeking an expedited meeting with the FDA to discuss options.

Shares of Hemispherx fell 59 cents, or 49 percent, to 61 cents in premarket trading Wednesday. The stock closed at $1.20 during the regular trading session Tuesday.

E-mail E-mail article      Print Print      Share Share

More Business & Technology

UPDATE - 09:46 AM
Exxon Mobil wins ruling in Alaska oil spill case

UPDATE - 09:32 AM
Bank stocks push indexes higher; oil prices dip

UPDATE - 08:04 AM
Ford CEO Mulally gets $56.5M in stock award

UPDATE - 07:54 AM
Underwater mortgages rise as home prices fall

NEW - 09:43 AM
Warner Bros. to offer movie rentals on Facebook

More Business & Technology headlines...

Comments
No comments have been posted to this article.

advertising


Get home delivery today!

Video

Advertising

AP Video

Entertainment | Top Video | World | Offbeat Video | Sci-Tech

Marketplace

 
Most read
Most commented
Most e-mailed
 
 

Most viewed imagesMore

Advertising